Acrivon Therapeutics, Inc. (ACRV)
Acrivon Therapeutics is a clinical stage biopharmaceutical company developing precision oncology medicines that we match to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing our proprietary proteomics-based patient responder identification platform.
Our approach is designed to overcome the limitations of genomics-based patient selection methods. We do this by using our proprietary precision medicine platform, Acrivon Predictive Precision Proteomics, or AP3, to develop our pipeline of oncology drug candidates.
Our AP3 platform enables the creation of drug-specific proprietary OncoSignature companion diagnostics that are used to identify the patients most likely to benefit from our drug candidates, which we refer to as patient responders.
We are currently advancing our lead candidate, ACR-368, in a potentially registrational Phase 2 trial across multiple tumor types, which our AP3 platform predicts will have a high proportion of patient responders based on OncoSignature-predicted sensitivity to ACR-368.
Initially, patients with platinum-resistant ovarian, endometrial, or bladder cancer will be treated in this trial.
We also plan to study ACR-368 in additional indications, such as human papilloma virus positive, squamous cell carcinomas, including squamous cell cancer of head and neck, anal, and cervical cancer.
|IPO Date||Nov 15, 2022|
|CEO||Peter Blume-Jensen, M.D., Ph.D.|
480 Arsenal Way, Suite 100
Watertown, MA 02472
|Fiscal Year End||December|
|Peter Blume-Jensen, M.D., Ph.D.||Chief Executive Officer, President and Chairman of the Board|
|Rasmus Holm-Jorgensen||Chief Financial Officer|
|Erick Gamelin, M.D., Ph.D.||Chief Medical Officer|
|Kristina Masson, Ph.D.||Executive Vice President, Business Operations, Director|
|Eric Devroe, Ph.D.||Chief Operating Officer|
|Derek DiRocco, Ph.D.||Director|
|Sharon Shacham, Ph.D., M.B.A.||Director|
|Michael Tomsicek, M.B.A.||Director|
Latest SEC Filings
|Nov 28, 2022||SC 13D||General statement of acquisition of beneficial ownership|
|Nov 28, 2022||SC 13G||Statement of acquisition of beneficial ownership by individuals|
|Nov 25, 2022||SC 13G||Statement of acquisition of beneficial ownership by individuals|
|Nov 21, 2022||SC 13G||Statement of acquisition of beneficial ownership by individuals|
|Nov 18, 2022||SC 13G||Statement of acquisition of beneficial ownership by individuals|
|Nov 17, 2022||8-K||Current Report|
|Nov 17, 2022||S-8||Securities to be offered to employees in employee benefit plans|
|Nov 16, 2022||424B4||Prospectus|
|Nov 14, 2022||S-1MEF||Registration adding securities to prior Form S-1 registration|
|Nov 14, 2022||FWP||Free Writing Prospectus|